Questions? Feedback? powered by Olark live chat software

Parkinson's Disease

Parkinson's disease is a neurodegenerative disease characterized by muscle tremors, trouble balancing, stiffness in limbs, and bradykinesia (slowness of movement). Parkinson's disease progresses slowly and is often times diagnosed later in life. The neurotransmitter dopamine plays an integral role in the progression of Parkinson's disease. Dopamine is necessary to control mood, muscle movements, and learning. In the brains of those suffering from Parkinson's disease, the majority of dopamine producing cells are damaged. The neuro-degeneration is progressive and worsens as time goes on. Treatment is available to improve some of the symptoms of Parkinson's. The treatment is centered on the neurotransmitter dopamine, and administered in the form of a dopamine pre-cursor called L-dopa. Some early symptoms of Parkinson's disease include shaking, small handwriting, loss of smell, trouble sleeping, constipation, having a low or soft voice, masked face appearance, dizziness, and stooping posture. When therapy with medications has not been successful, there are surgical procedures to help those suffering from Parkinson's disease. Deep brain stimulation is a surgical process in which a neurostimulator is implanted in the brain to deliver electrical stimulation to targeted areas of the brain that control movement. This stimulation can block misdirected nerve signals that cause tremors.

Anti-TRPM7 antibody binds against the target antigen TRPM7. Transient receptor potential cation channel subfamily M member 7 is expressed in the cell membrane. TRPM7 is an essential ion channel that is permeable to calcium and magnesium. TRPM7 plays a role in the regulation of anoxic neuronal cell death. Defects in TRPM7 are a cause of susceptibility to amyotrophic lateral sclerosis-parkinsonism/dementia complex type 1. ALS, or Lou Gehrig's Disease, is a familial disorder characterized by a loss of lower motor neurons leading to progressive muscle weakness and atrophy leading to difficulty breathing, difficulty swallowing, muscle cramps, paralysis, hoarseness in voice, weight loss, and muscle contractions. Anti-ALDH1A1 antibody binds against acetaldehyde dehydrogenase 1 and is localized in the cytoplasm of cells. ALDH1A1 binds to free retinal and can convert by oxidizing retinaldehyde to retinoic acid.

 
Product Number Title Applications Host Clonality
AC21-2736 Anti-Alpha Synuclein Antibody ELISA, WB Goat Polyclonal
AC21-2737 Anti-Alpha Synuclein Antibody ELISA, WB Goat Polyclonal
AC21-0030-01 Anti-ALDH1A1 Antibody (AMCA) ELISA, WB, IHC Goat Polyclonal
AC21-0030-02 Anti-ALDH1A1 Antibody (AP) ELISA, WB, IHC Goat Polyclonal
AC21-0030-03 Anti-ALDH1A1 Antibody (APC) ELISA, WB, IHC Goat Polyclonal
AC21-0030-04 Anti-ALDH1A1 Antibody (APC-Cy5.5) ELISA, WB, IHC Goat Polyclonal
AC21-0030-05 Anti-ALDH1A1 Antibody (APC-Cy7) ELISA, WB, IHC Goat Polyclonal
AC21-0030-06 Anti-ALDH1A1 Antibody (Avidin) ELISA, WB, IHC Goat Polyclonal
AC21-0030-07 Anti-ALDH1A1 Antibody (Biotin) ELISA, WB, IHC Goat Polyclonal
AC21-0030-08 Anti-ALDH1A1 Antibody (BPE) ELISA, WB, IHC Goat Polyclonal
AC21-0030-09 Anti-ALDH1A1 Antibody (Cy3) ELISA, WB, IHC Goat Polyclonal
AC21-0030-10 Anti-ALDH1A1 Antibody (Cy5) ELISA, WB, IHC Goat Polyclonal